Key result
Carvedilol lowers systemic and regional vascular resistance via complementary beta-blockade and alpha-1-mediated vasodilation.
Why the study?
Carvedilol's dual beta-blockade and vasodilation effects occur in the same dose range, but the mechanisms and contributions to hemodynamic effects require clarification.
Does carvedilol reduce regional and systemic vascular resistance in experimental models, healthy volunteers, and patients with cardiovascular diseases?
Does carvedilol reduce regional and systemic vascular resistance in experimental models, healthy volunteers, and patients with cardiovascular diseases?
Carvedilol provides dual beta-blockade and alpha-1 mediated vasodilation, effectively reducing vascular resistance in patients with cardiovascular diseases.
Reinforces carvedilol selection for resistance reduction; confirms dual mechanism yet leaves open outcome trials.
Carvedilol is a dual-acting drug designed to produce two complementary effects: beta-blockade and vasodilation. These effects are induced in the same dose range, a prerequisite for utilizing both properties in an appropriate manner. The vasodilation is mediated predominantly by specific alpha 1-adrenoceptor blockade. At markedly higher concentrations, additional vasodilating actions besides alpha 1-blockade can be observed. These effects resemble those of Ca(2+)-antagonistic properties. However, they do not contribute to the acute blood pressure-lowering activity of carvedilol but may be responsible for the increased blood flow to specific organs. At beta-blocking doses, carvedilol reduces the regional and systemic vascular resistance in various experimental models, healthy volunteers, and in patients with cardiovascular diseases such as hypertension, coronary artery disease, and heart failure. The profile of carvedilol thus insures beneficial treatment of hemodynamic disorders characterized by increased sympathetic tone and increased vascular resistance.
No takes yet. Share an insight, caveat, or question.
Sponer et al. (1992) conducted a review in Cardiovascular diseases (hypertension, coronary artery disease, heart failure). Carvedilol was evaluated. Carvedilol provides complementary beta-blockade and alpha-1-adrenoceptor-mediated vasodilation, reducing regional and systemic vascular resistance in patients with cardiovascular diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: